Alberta Investment Management Corp Buys Shares of 10,199 Bruker Co. (NASDAQ:BRKR)

Alberta Investment Management Corp bought a new stake in Bruker Co. (NASDAQ:BRKR) during the 4th quarter, Holdings Channel reports. The firm bought 10,199 shares of the medical research company’s stock, valued at approximately $598,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its stake in shares of Bruker by 51.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 210,761 shares of the medical research company’s stock valued at $14,555,000 after acquiring an additional 71,275 shares during the period. Values First Advisors Inc. purchased a new stake in shares of Bruker in the 3rd quarter valued at approximately $73,000. Louisiana State Employees Retirement System raised its stake in shares of Bruker by 11.3% in the 3rd quarter. Louisiana State Employees Retirement System now owns 30,600 shares of the medical research company’s stock valued at $2,113,000 after acquiring an additional 3,100 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in shares of Bruker by 109.9% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 13,110 shares of the medical research company’s stock valued at $905,000 after acquiring an additional 6,863 shares during the period. Finally, Boston Trust Walden Corp purchased a new stake in shares of Bruker in the 3rd quarter valued at approximately $207,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Trading Down 4.0 %

NASDAQ BRKR opened at $50.82 on Friday. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. Bruker Co. has a 52 week low of $48.07 and a 52 week high of $94.86. The stock has a market capitalization of $7.70 billion, a PE ratio of 66.87, a price-to-earnings-growth ratio of 2.16 and a beta of 1.16. The firm has a 50 day moving average of $56.73 and a two-hundred day moving average of $60.03.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. As a group, research analysts expect that Bruker Co. will post 2.69 EPS for the current fiscal year.

Analyst Ratings Changes

BRKR has been the topic of a number of research analyst reports. Wells Fargo & Company reduced their price target on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Citigroup cut their target price on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a research note on Friday, January 17th. TD Cowen cut their target price on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. Finally, Bank of America upped their target price on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $70.50.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.